House Subcommittees Solicit Mobile Health App Testimony
March 19—Three House subcommittee hearings this week will focus on mobile healthcare applications—especially how the 2.3 percent medical device tax and pending guidelines from the Food and Drug Administration (FDA) will affect the development and use of those apps.
During the hearings, industry experts will address healthcare IT topics including harnessing wireless innovation, how innovation benefits patients, and administration perspectives on innovation and regulation.
In Tuesday’s hearing before the House Committee on Energy and Commerce’s Communications and Technology Subcommittee, participants urged the FDA to finalize its July 2011 draft guidance. That guidance would clarify which mobile medical applications and devices are subject to the 2.3 percent medical device tax. One participant expressed concern that the tax, if applied broadly, could restrict innovation by discouraging venture capitalists from investing in nascent mobile medical application developers and could basically result in a “revenue tax.” Most participants agreed FDA oversight was needed on mobile medical applications that involve making a clinical decision when used by physicians or patients, such as an app detecting whether a mole might be cancerous.
Publication Date: Tuesday, March 19, 2013